(Q28258072)

1

0 references

James E Wraith

2

0 references

Michael Beck

3

0 references

Paul Harmatz

5

0 references

Christine M Eng

6

0 references

Ashok Vellodi

7

0 references

Rick Martin

8

0 references

Uma Ramaswami

9

0 references

Muge Gucsavas-Calikoglu

10

0 references

Suresh Vijayaraghavan

11

0 references

Susanne Wendt

12

0 references

Suzanne Wendt

13

0 references

Ana Cristina Puga

14

0 references

Antonio Puga

15

0 references

Brian Ulbrich

16

0 references

Marwan Shinawi

17

0 references

Maureen Cleary

18

0 references

Diane Piper

19

0 references

Anne Marie Conway

20

0 references

Ann Marie Conway

21

0 references

Alan Kimura

Prevalence of lysosomal storage disorders

22

0 references

language of work or name

English

0 references

publication date

August 2006

0 references

published in

Genetics in Medicine

0 references

volume

8

0 references

issue

8

0 references

page(s)

465-73

0 references

cites work

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

The frequency of lysosomal storage diseases in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Incidence of Hunter's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Molecular and phenotypic variation in patients with severe Hunter syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease)

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Procedures for comparing samples with multiple endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Standardization of Spirometry, 1994 Update. American Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Spirometric reference values from a sample of the general U.S. population

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Enzyme-replacement therapy in mucopolysaccharidosis I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Volume of the spleen in children as measured on CT scans: normal standards as a function of body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Long-term follow-up following bone marrow transplantation for Hunter disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.GIM.0000232477.37660.FB

10.1097/01.GIM.0000232477.37660.FB

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1037860924

0 references

Fatcat ID

release_bqbycfj5gbhtng76fk3izakama

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bqbycfj5gbhtng76fk3izakama

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16912578

1 reference

Consolidated OpenCitations Corpus – April 2017